ATPW
SWTX

Ashton Thomas Private Wealth’s SpringWorks Therapeutics SWTX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-345
Closed -$13K – 1693
2024
Q2 		$13K Buy
+345
New +$14.5K ﹤0.01% 1267

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Ashton Thomas Private Wealth's SWTX Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of SpringWorks Therapeutics (SWTX) in Q3 2024, closing a stake of 345 shares — an estimated $13K sold.

Ashton Thomas Private Wealth first reported a position in SWTX in Q2 2024 and held it in 1 quarter. The position peaked at $13K in Q2 2024. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • Ashton Thomas Private Wealth reported no remaining SpringWorks Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 345 SpringWorks Therapeutics shares in Q3 2024, an estimated $13K.
  • Ashton Thomas Private Wealth first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 1 quarter.
  • Ashton Thomas Private Wealth's SpringWorks Therapeutics position peaked at $13K in Q2 2024.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.